Nuvalent (NUVL) Preferred Shares Issued (2020 - 2021)

Nuvalent (NUVL) reported Preferred Shares Issued of $134.7 million for Q2 2021, up 1246.52% quarter-over-quarter from $10.0 million in Q1 2021.

Nuvalent (NUVL) Preferred Shares Issued (2020 - 2021) Analysis & Trends

Nuvalent has reported Preferred Shares Issued for 2 years, with the latest figure at $134.7 million in Q2 2021.

For the quarter ending Q2 2021, Preferred Shares Issued changed N/A year-over-year to $134.7 million; the trailing twelve-month figure through Dec 2021 stood at $144.7 million (changed N/A YoY), and the FY2021 full-year result was $144.7 million, up 542.9% from the prior year.
Preferred Shares Issued for Q2 2021 stood at $134.7 million, up from $10.0 million in the prior quarter.
The five-year high for Preferred Shares Issued was $134.7 million in Q2 2021, with the low at $10.0 million in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Shares Issued (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	-
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	Nuvalent	9.70 Bn	9.70 Bn	-	-

Download Data